Skip to main content
72°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
RLFTY
)
1.470
UNCHANGED
Streaming Delayed Price
Updated: 2:57 PM EDT, Aug 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about RLFTY
< Previous
1
2
3
4
Next >
Relief Therapeutics Provides an Update on its Financing Strategy
February 08, 2023
Via
ACCESSWIRE
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
January 17, 2023
Via
ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
December 27, 2022
Via
ACCESSWIRE
Relief Announces U.S. Launch of PKU GOLIKE
October 10, 2022
Via
ACCESSWIRE
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
October 06, 2022
Via
ACCESSWIRE
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
August 17, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
December 20, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in January Investor Meetings
December 14, 2022
Via
ACCESSWIRE
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement
October 26, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
October 25, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
October 14, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
September 22, 2022
Via
ACCESSWIRE
Relief Reports Half-Year 2022 Results and Provides Corporate Update
September 15, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
September 12, 2022
Via
ACCESSWIRE
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
Via
ACCESSWIRE
Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission
August 24, 2022
Via
ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation
August 22, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)
August 03, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
July 21, 2022
Via
ACCESSWIRE
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
July 21, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief ") announced today that the U.S. Securities and Exchange Commission (" SEC ")...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)
July 18, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 18, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), today announced that its collaboration partner, ACER Therapeutics, Inc....
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
Product Safety
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
July 18, 2022
Experienced Leader in Commercial and Medical Affairs, With a Focus on Gene Therapy, to Spearhead Relief's New Strategic Foray Into Genetic Medicine
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
July 13, 2022
Company acquires an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exception of the United Kingdom, thereby complementing and enhancing its...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
Product Safety
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
July 04, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
July 04, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 4 to its Registration...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
June 13, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / June 13, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
Product Safety
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
June 17, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / June 17, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), announced today that it has filed Amendment No. 3 to its Registration...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
June 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / June 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief " or the " Company "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
June 08, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / June 8, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
Product Safety
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients
May 31, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.